All In Biotech

Drug Trial Radar · NCT05489237

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

276

Actual

Start

Aug 3, 2022

Primary completion

Mar 10, 2027

Study completion Mar 26, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.

Conditions

  • Gastrointestinal Neoplasms
  • Gastrointestinal Stromal Tumor (GIST)
  • Digestive System Disease
  • Gastrointestinal Diseases
  • Metastatic Cancer

Interventions

  • IDRX-42Drug

    Administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)Time frame: When participant completes 1 cycle (28 days) treatment with safety and tolerability assessment by investigators
  2. Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)Time frame: Approximately 18 months from first participant enrolled
  3. Phase 1 (Dose Escalation) - Determination of the MTD and/or RP1bD(s) of orally administered IDRX-42Time frame: Approximately 18 months from first participant enrolled
  4. Phase 1 (Dose Escalation) - C-QTc sub-study: QTcF - concentration response analysisTime frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
  5. Phase 1b-Number of participants with TEAEs and with laboratory test resultsTime frame: Approximately 18 months
  6. Phase 1b - Objective Response Rate (ORR) mRESIST v1.1Time frame: Approximately 18 months
  7. Phase 1b - C-QTcF sub-study: QTcF - concentration response analysisTime frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)

Locations

31 sites in 11 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Portland, Oregon

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Leuven, Belgium

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Wuhan, China

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Marseille, France

  • GSK Investigational Site

    Villejuif, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Essen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Amsterdam, Netherlands

  • GSK Investigational Site

    Rotterdam, South Holland, Netherlands

  • GSK Investigational Site

    Seongnam-si Gyeonggi-do, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    London, United Kingdom

  • GSK Investigational Site

    Leeds, West Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.